Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483680 | 1.00 | FAAH (0.48) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL15483681 | 1.00 | FAAH (0.48) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL19359752 | 1.00 | FAAH (0.48) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL15483679 | 0.96 | MGLL (0.46) | — | |
| SCHEMBL19359797 | 0.88 | FAAH (0.45) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL18856384 | 0.88 | FAAH (0.45) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL17132403 | 0.88 | ALDH1A1 (0.48) | — | |
| SCHEMBL10087817 | 0.88 | ALDH1A1 (0.48) | — | |
| SCHEMBL12438288 | 0.87 | FAAH (0.47) | FAAHEPHX2PRKCEPRKCQPRKCD | |
| SCHEMBL12117507 | 0.87 | FAAH (0.47) | FAAHEPHX2PRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | FAAH 3072/4885EPHX2 880/4885PRKCE 2537/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | FAAH 3072/4885EPHX2 880/4885PRKCE 2537/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | FAAH 1017/4885EPHX2 2191/4885PRKCE 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.